|
1
|
Foukakis T, Lundell L, Gubanski M and Lind
PA: Advances in the treatment of patients with gastric
adenocarcinoma. Acta Oncol. 46:277–285. 2007. View Article : Google Scholar
|
|
2
|
Tomasetti M, Gellert N, Procopio A and
Neuzil J: A vitamin E analogue suppresses malignant mesothelioma in
a preclinical model: a future drug against a fatal neoplastic
disease? Int J Cancer. 109:641–642. 2004. View Article : Google Scholar
|
|
3
|
Neuzil J, Weber T, Gellert N and Weber C:
Selective cancer cell killing by alpha-tocopheryl succinate. Br J
Cancer. 84:87–89. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Malafa MP, Fokum FD, Mowlavi A, Abusief M
and King M: Vitamin E inhibits melanoma growth in mice. Surgery.
131:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kline K, Yu W and Sanders BG: Vitamin E
and breast cancer. J Nutr. 134:S3458–S3462. 2004.
|
|
6
|
Wu K, Zhao Y, Liu BH, et al:
RRR-alpha-tocopheryl succinate inhibits human gastric cancer
SGC-7901 cell growth by inducing apoptosis and DNA synthesis
arrest. World J Gastroenterol. 8:26–30. 2002.PubMed/NCBI
|
|
7
|
Dong LF, Jameson VJ, Tilly D, et al:
Mitochondrial targeting of vitamin E succinate enhances its
pro-apoptotic and anti-cancer activity via mitochondrial complex
II. J Biol Chem. 286:3717–3728. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu K, Li Y, Zhao Y, et al: Roles of Fas
signaling pathway in vitamin E succinate-induced apoptosis in human
gastric cancer SGC-7901 cells. World J Gastroenterol. 8:982–986.
2002.PubMed/NCBI
|
|
9
|
Wu K, Zhao Y, Li GC and Yu WP: c-Jun
N-terminal kinase is required for vitamin E succinate-induced
apoptosis in human gastric cancer cells. World J Gastroenterol.
10:1110–1114. 2004.PubMed/NCBI
|
|
10
|
Huang X, Zhang Z, Jia L, Zhao Y, Zhang X
and Wu K: Endoplasmic reticulum stress contributes to vitamin E
succinate-induced apoptosis in human gastric cancer SGC-7901 cells.
Cancer Lett. 296:123–131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo JL, Zheng SJ, Li YN, et al:
Toxicarioside A inhibits SGC-7901 proliferation, migration and
invasion via NF-κB/bFGF signaling. World J Gastroenterol.
18:1602–1609. 2012.PubMed/NCBI
|
|
12
|
Long YM, Ye S, Rong J and Xie WR: Nuclear
factor kappa B: a marker of chemotherapy for human stage IV gastric
carcinoma. World J Gastroenterol. 14:4739–4744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K and
Qin ZH: Blocking NF-kappaB nuclear translocation leads to
p53-related autophagy activation and cell apoptosis. World J
Gastroenterol. 17:478–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X and Stark GR: NFkappaB-dependent
signaling pathways. Exp Hematol. 30:285–296. 2002. View Article : Google Scholar
|
|
15
|
Karin M and Lin A: NF-kappaB at the
crossroads of life and death. Nat Immunol. 3:221–227. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilmore TD: The Re1/NF-kappa B/I kappa B
signal transduction pathway and cancer. Cancer Treat Res.
115:241–265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bharti AC and Aggarwal BB: Nuclear
factor-kappa B and cancer: its role in prevention and therapy.
Biochem Pharmacol. 64:883–888. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB
in lung cancer, a carcinogenesis mediator and a prevention and
therapy target. Front Biosci. 16:1172–1185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sebens S, Arlt A and Schafer H: NF-kappaB
as a molecular target in the therapy of pancreatic carcinoma.
Recent Results Cancer Res. 177:151–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu K, Shan YJ, Zhao Y, Yu JW and Liu BH:
Inhibitory effects of RRR-alpha-tocopheryl succinate on
benzo(a)pyrene (B(a)P)-induced forestomach carcinogenesis in female
mice. World J Gastroenterol. 7:60–65. 2001.PubMed/NCBI
|
|
21
|
Zhang X, Peng X, Yu W, et al:
Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis
in human gastric cancer cells via promotion of doxorubicin influx
and suppression of doxorubicin efflux. Cancer Lett. 307:174–181.
2011. View Article : Google Scholar
|
|
22
|
Huang X, Li L, Zhang L, et al: Crosstalk
between endoplasmic reticulum stress and oxidative stress in
apoptosis induced by alpha-tocopheryl succinate in human gastric
carcinoma cells. Br J Nutr. 109:1–9. 2013. View Article : Google Scholar
|
|
23
|
Chen X, Kandasamy K and Srivastava RK:
Differential roles of RelA (p65) and c-Rel subunits of nuclear
factor kappa B in tumor necrosis factor-related apoptosis-inducing
ligand signaling. Cancer Res. 63:1059–1066. 2003.PubMed/NCBI
|
|
24
|
Sun SC and Xiao G: Deregulation of
NF-kappaB and its upstream kinases in cancer. Cancer Metastasis
Rev. 22:405–422. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin A and Karin M: NF-kappaB in cancer: a
marked target. Semin Cancer Biol. 13:107–114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neuzil J, Svensson I, Weber T, Weber C and
Brunk UT: alpha-tocopheryl succinate-induced apoptosis in Jurkat T
cells involves caspase-3 activation, and both lysosomal and
mitochondrial destabilisation. FEBS Lett. 445:295–300. 1999.
View Article : Google Scholar
|
|
27
|
Wang XF, Witting PK, Salvatore BA and
Neuzil J: Vitamin E analogs trigger apoptosis in
HER2/erbB2-overexpressing breast cancer cells by signaling via the
mitochondrial pathway. Biochem Biophys Res Commun. 326:282–289.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu W, Sanders BG and Kline K:
RRR-alpha-tocopheryl succinate-induced apoptosis of human breast
cancer cells involves Bax translocation to mitochondria. Cancer
Res. 63:2483–2491. 2003.PubMed/NCBI
|
|
29
|
Crispen PL, Uzzo RG, Golovine K, et al:
Vitamin E succinate inhibits NF-kappaB and prevents the development
of a metastatic phenotype in prostate cancer cells: implications
for chemoprevention. Prostate. 67:582–590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dalen H and Neuzil J: Alpha-tocopheryl
succinate sensitises a T Lymphoma cell line to TRAIL-induced
apoptosis by suppressing NF-kappaB activation. Br J Cancer.
88:153–158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mitsiades N, Mitsiades CS, Richardson PG,
et al: The proteasome inhibitor PS-341 potentiates sensitivity of
multiple myeloma cells to conventional chemotherapeutic agents:
therapeutic applications. Blood. 101:2377–2380. 2003. View Article : Google Scholar
|
|
32
|
Zheng B, Georgakis GV, Li Y, et al:
Induction of cell cycle arrest and apoptosis by the proteasome
inhibitor PS-341 in Hodgkin disease cell lines is independent of
inhibitor of nuclear factor-kappaB mutations or activation of the
CD30, CD40, and RANK receptors. Clin Cancer Res. 10:3207–3215.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cilloni D, Messa F, Arruga F, et al: The
NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome
imatinib resistance. Leukemia. 20:61–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dai Y, Pei XY, Rahmani M, Conrad DH, Dent
P and Grant S: Interruption of the NF-kappaB pathway by Bay 11-7082
promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in
human multiple myeloma cells. Blood. 103:2761–2770. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H and Lin X: Positive and negative
signaling components involved in TNFalpha-induced NF-kappaB
activation. Cytokine. 41:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Müerköster S, Arlt A, Sipos B, et al:
Increased expression of the E3-ubiquitin ligase receptor subunit
betaTRCP1 relates to constitutive nuclear factor-kappaB activation
and chemoresistance in pancreatic carcinoma cells. Cancer Res.
65:1316–1324. 2005.
|
|
37
|
Viatour P, Bentires-Alj M, Chariot A, et
al: NF-kappa B2/p100 induces Bcl-2 expression. Leukemia.
17:1349–1356. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Al-Harbi S, Hill BT, Mazumder S, et al: An
antiapoptotic BCL-2 family expression index predicts the response
of chronic lymphocytic leukemia to ABT-737. Blood. 118:3579–3590.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pop C and Salvesen GS: Human caspases:
activation, specificity, and regulation. J Biol Chem.
284:21777–21781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Olsson M and Zhivotovsky B: Caspases and
cancer. Cell Death Differ. 18:1441–1449. 2011. View Article : Google Scholar
|
|
43
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gyrd-Hansen M, Darding M, Miasari M, et
al: IAPs contain an evolutionarily conserved ubiquitin-binding
domain that regulates NF-kappaB as well as cell survival and
oncogenesis. Nat Cell Biol. 10:1309–1317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Trocoli A and Djavaheri-Mergny M: The
complex interplay between autophagy and NF-kappaB signaling
pathways in cancer cells. Am J Cancer Res. 1:629–649.
2011.PubMed/NCBI
|
|
46
|
Neuzil J, Tomasetti M, Zhao Y, et al:
Vitamin E analogs, a novel group of “mitocans,” as anticancer
agents: the importance of being redox-silent. Mol Pharmacol.
71:1185–1199. 2007.
|
